Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AMLN (DIABETES DRUGS) -- Ignore unavailable to you. Want to Upgrade?

To: D.Right who wrote (964)	11/20/1997 6:46:00 PM
From: David Bogdanoff	Read Replies (1) \| Respond to of 2173

DR: I believe the patent protection is now 19 years from the date granted, not the start of marketing. Althought patents are not forever, most companies can effectively extend the patent by developing more advanced versions of the drug and getting new patents. More importantly, AMLN is not a one product company by any means, which can be ascertained by looking a recent news of deals with other companies. David PS: Many followers of Murphy feel that his earnings estimates are much too high. My own view of AMLN's worth is determined more by J&Js financial committment to it.